Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.
about
Statins but not fibrates improve the atherogenic to anti-atherogenic lipoprotein particle ratio: a randomized crossover study.Differential effects of fenofibrate versus atorvastatin on the concentrations of E-selectin and vascular cellular adhesion molecule-1 in patients with type 2 diabetes mellitus and mixed hyperlipoproteinemia: a randomized cross-over trialFenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a reviewPharmacologic treatment of type 2 diabetic dyslipidemia.Effect of lipid-lowering drug therapy on small-dense low-density lipoprotein.Evaluation of lipid profiles and the use of omega-3 essential Fatty Acid in professional football players.Low-density lipoprotein size and cardiovascular risk assessment.Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating RosBeneficial effects of the addition of fenofibrate to statin therapy in patients with acute coronary syndrome after percutaneous coronary interventions.Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles.Fibrates: what have we learned in the past 40 years?Activation of peroxisome proliferator-activated receptor-alpha in mice induces expression of the hepatic low-density lipoprotein receptor.A comparative study of efficacy of atorvastatin alone and its combination with fenofibrate on lipid profile in type 2 diabetes mellitus patients with hyperlipidemiaEffects of atorvastatin 10 mg and fenofibrate 200 mg on the low-density lipoprotein profile in dyslipidemic patients: A 12-week, multicenter, randomized, open-label, parallel-group study.Epanova(®) and hypertriglyceridemia: pharmacological mechanisms and clinical efficacy.Statins, fibrates, thiazolidinediones and resveratrol as adjunctive therapies in sepsis: could mitochondria be a common target?Niacin treatment of the atherogenic lipid profile and Lp(a) in diabetes.Effects of atorvastatin on low-density lipoprotein cholesterol phenotype and C-reactive protein levels in patients undergoing long-term dialysis.A double-blind, randomised trial of tesaglitazar versus pioglitazone in patients with type 2 diabetes mellitus.Atorvastatin or fenofibrate on post-prandial lipaemia in type 2 diabetic patients with hyperlipidaemia.CVD Risk Stratification in the PCSK9 Era: Is There a Role for LDL Subfractions?
P2860
Q21262011-EB2A5ED7-BA5D-4A73-983F-39FAA652F565Q24806105-4E193357-32AD-4780-85DA-64EAEE2D500FQ28220294-CB326FB5-4E85-4A34-B19E-1D4ECF2A2A22Q35976827-639D6695-F72E-47F8-ACB2-C08E50460A7CQ36020263-F7949BEC-7B67-4712-8051-B7F83BD011C7Q36242160-10C66BFA-DCF3-4896-8D7D-76A68C2C525BQ36349994-B34127B4-66F8-4415-8EB1-BC4A9ED06D1AQ36359891-9DF2F0BE-F209-4746-96F0-A62799A7C6A2Q36608415-6691BCA5-AB87-425A-9628-5AD8324C5BC9Q36675450-F2317CBE-CA34-4E69-BB37-6CE174843D54Q36742410-B7BF5441-5185-4E68-824E-84187EFA4868Q36842486-87BB6B9B-7D49-4F74-AA2E-34CAC2982074Q37183153-CC2874DF-FBBE-42A3-92FB-ACCC0105114CQ37667470-F5E1F736-F6AB-4B29-856A-2C3A80A5E1BEQ38086841-0FFDC936-5E06-4E30-88C3-D7C8B378F0D7Q38565307-ECAF77CE-C224-425E-994C-6C5A9506675DQ44051686-3660B8C8-F98C-4D71-8BC0-514AB08D67B4Q46447884-807A340E-88F9-4020-B82D-9209273E3073Q46973482-98E0A2A7-D455-460D-8023-B1D4A2EB75A4Q51492959-FD78819D-3AB0-44BD-8D73-CA280FD60F3FQ55409636-D7F54E5A-7BEE-4948-B7E2-FBEEFF6AFD71
P2860
Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
name
Effects of atorvastatin versus ...... th mixed hyperlipoproteinemia.
@ast
Effects of atorvastatin versus ...... th mixed hyperlipoproteinemia.
@en
type
label
Effects of atorvastatin versus ...... th mixed hyperlipoproteinemia.
@ast
Effects of atorvastatin versus ...... th mixed hyperlipoproteinemia.
@en
prefLabel
Effects of atorvastatin versus ...... th mixed hyperlipoproteinemia.
@ast
Effects of atorvastatin versus ...... th mixed hyperlipoproteinemia.
@en
P2093
P1476
Effects of atorvastatin versus ...... th mixed hyperlipoproteinemia.
@en
P2093
P356
10.1016/S0002-9149(00)01270-4
P407
P577
2001-01-01T00:00:00Z